Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Indiana’s Medicaid program estimates the Biden administration’s proposal to expand coverage of weight-loss treatment for ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...